Complete financial analysis of Soleno Therapeutics, Inc. (SLNO) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Soleno Therapeutics, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Tower Resources Ltd. (TWR.V) Income Statement Analysis – Financial Results
- Brookfield Asset Management Inc. PFD SR 48 CL A (BAM-PFJ.TO) Income Statement Analysis – Financial Results
- Alpha Cognition Inc. Common Stock (ACOG) Income Statement Analysis – Financial Results
- Allied Healthcare Products, Inc. (AHPIQ) Income Statement Analysis – Financial Results
- Beijing eGOVA Co,. Ltd (300075.SZ) Income Statement Analysis – Financial Results
Soleno Therapeutics, Inc. (SLNO)
About Soleno Therapeutics, Inc.
Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Controlled-Release, a once-daily oral tablet for the treatment of Prader-Willi Syndrome, which is being evaluated in an ongoing Phase III clinical development program. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was incorporated in 1999 and is based in Redwood City, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -1.55B | 1.45M | 387.56K | 0.00 | 3.00M | 0.00 |
| Cost of Revenue | 1.96M | 2.21M | 2.21M | 2.19M | 2.30M | 1.92M | 1.61M | 1.51M | 352.68K | 0.00 | 0.00 | 0.00 |
| Gross Profit | -1.96M | -2.21M | -2.21M | -2.19M | -2.30M | -1.92M | -1.55B | -58.52K | 34.87K | 0.00 | 3.00M | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 100.10% | -4.03% | 9.00% | 0.00% | 100.00% | 0.00% |
| Research & Development | 25.19M | 15.27M | 21.45M | 23.19M | 16.27M | 7.18M | 3.07M | 5.18M | 4.54M | 2.24M | 2.38M | 2.47M |
| General & Administrative | 13.48M | 9.84M | 10.81M | 8.76M | 6.93M | 6.56M | 6.58M | 6.74M | 6.14M | 2.67M | 1.47M | 1.13M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 25.73K | 1.63M | 1.74M | 252.36K | 0.00 | 0.00 |
| SG&A | 13.48M | 9.84M | 10.81M | 8.76M | 6.93M | 6.56M | 6.61M | 8.37M | 7.88M | 2.92M | 1.47M | 1.13M |
| Other Expenses | 2.71M | 0.00 | 0.00 | 4.34M | 289.00K | 6.00K | -585.95K | -100.52K | -183.57K | -4.59M | -1.97K | -22.41K |
| Operating Expenses | 41.38M | 25.11M | 32.26M | 31.95M | 23.20M | 13.73M | 9.68M | 13.55M | 12.19M | 5.16M | 3.85M | 3.60M |
| Cost & Expenses | 41.38M | 25.11M | 32.26M | 31.95M | 23.20M | 13.73M | 9.68M | 15.06M | 12.55M | 5.16M | 3.85M | 3.60M |
| Interest Income | 2.58M | 300.00K | 110.00K | 13.00K | 154.00K | 0.00 | 0.00 | 0.00 | 0.00 | 1.09K | 1.77K | 3.10K |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 62.00K | 0.00 | 0.00 | 0.00 | 4.13M | 2.86M | 2.87M |
| Depreciation & Amortization | 1.96M | 2.21M | 2.21M | 2.19M | 2.30M | 1.92M | 1.61M | 19.70K | 108.23K | 28.52K | 42.11K | 43.79K |
| EBITDA | -37.03M | -21.86M | -28.70M | -30.00M | -28.48M | -9.92M | -8.07M | -6.72M | -15.80M | -5.13M | -804.86K | -3.57M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.30% | -1,043.96% | -3,943.82% | 0.00% | -26.83% | 0.00% |
| Operating Income | -41.38M | -24.40M | -31.53M | -36.29M | -23.49M | -14.30M | -12.17M | -13.61M | -12.16M | -5.16M | -846.78K | -3.60M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.78% | -938.12% | -3,137.55% | 0.00% | -28.23% | 0.00% |
| Total Other Income/Expenses | 2.40M | 330.00K | 618.00K | 11.65M | -7.29M | 2.46M | -1.27M | 1.59M | -3.75M | -8.08M | -2.86M | -2.88M |
| Income Before Tax | -38.99M | -24.07M | -30.91M | -24.64M | -30.77M | -11.84M | -13.72M | -12.04M | -15.91M | -13.87M | -3.71M | -6.48M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.88% | -830.14% | -4,104.85% | 0.00% | -123.57% | 0.00% |
| Income Tax Expense | 0.00 | -3.75M | -1.35M | -9.26M | 5.14M | 2.52M | -1.65M | 21.70K | -183.57K | -455.08K | 2.86M | 2.84M |
| Net Income | -38.99M | -20.32M | -29.56M | -15.38M | -35.92M | -13.34M | -15.67M | -12.07M | -15.91M | -13.87M | -3.71M | -6.48M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 1.01% | -831.63% | -4,104.85% | 0.00% | -123.57% | 0.00% |
| EPS | -2.36 | -2.42 | -5.56 | -3.68 | -15.78 | -9.54 | -26.18 | -58.35 | -126.58 | -819.38 | -198.45 | -346.98 |
| EPS Diluted | -2.36 | -2.42 | -5.56 | -3.68 | -15.78 | -9.54 | -26.18 | -58.35 | -126.58 | -819.38 | -198.45 | -346.98 |
| Weighted Avg Shares Out | 16.49M | 8.40M | 5.32M | 4.17M | 2.28M | 1.40M | 598.52K | 206.77K | 125.68K | 16.93K | 18.68K | 18.68K |
| Weighted Avg Shares Out (Dil) | 16.49M | 8.40M | 5.32M | 4.17M | 2.28M | 1.40M | 598.52K | 206.77K | 125.68K | 16.93K | 18.68K | 18.68K |
Soleno Stock Up as FDA Accepts PWS Drug NDA Under Priority Review
SLNO stock gains 6.3% as FDA accepts regulatory filing for lead candidate, DCCR, to treat hyperphagia associated with PWS under Priority Review.
Soleno Therapeutics: 2 New Catalysts To Bring Forth Change For PWS Patients
Soleno Therapeutics, Inc.'s NDA submission of DCCR for the treatment of patients with PWS accepted by the FDA with Priority Review with a PDUFA date of December 27th of 2024. Before the FDA PDUFA date of DCCR for the treatment...
Soleno Therapeutics Announces U.S. FDA Acceptance for Filing and Priority Review of NDA for DCCR (Diazoxide Choline) Extended-Release Tablets in Prader-Willi Syndrome
PDUFA target action date set for December 27, 2024 FDA currently plans to hold an Advisory Committee meeting REDWOOD CITY, Calif., Aug. 27, 2024 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics...
Soleno Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
REDWOOD CITY, Calif., Aug. 19, 2024 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced, as required by Nasdaq Stock Market rules, the grant of...
Soleno Therapeutics Announces Submission of New Drug Application to the U.S. FDA for DCCR (Diazoxide Choline) Extended-Release Tablets for the Treatment of Prader-Willi Syndrome
REDWOOD CITY, Calif., June 28, 2024 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced the submission of a New Drug Application (NDA) to the...
Soleno Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
REDWOOD CITY, Calif., June 24, 2024 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced, as required by Nasdaq Stock Market rules, the grant of...
SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Soleno Therapeutics, Inc. (NASDAQ: SLNO) and Encourages Long-Term Investors to Contact the Firm
PHILADELPHIA, PA / ACCESSWIRE / June 11, 2024 / Kaskela Law LLC announces that it is investigating Soleno Therapeutics, Inc. (NASDAQ:SLNO) ("Soleno") on behalf of the company's stockholders. The investigation seeks to determine whether Soleno and/or the company's officers and...
3 Stocks That Have Seen Higher Share Gains Than Super Micro Computer
One of the stocks to benefit the most from the artificial intelligence (AI) craze has been Super Micro Computer (Nasdaq: SMCI).
Soleno Therapeutics Announces Oral Presentation featuring DCCR (Diazoxide Choline) Extended-Release Tablets in Prader-Willi Syndrome at ENDO 2024
REDWOOD CITY, Calif., May 22, 2024 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that data from the randomized withdrawal period of Study C602...
Soleno Therapeutics to Participate in Upcoming Investor Conferences
REDWOOD CITY, Calif., May 22, 2024 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that Anish Bhatnagar, M.D., Chief Executive Officer, will participate in...
Source: https://incomestatements.info
Category: Stock Reports